Atrial Fibrillation in Patients Receiving Ibrutinib (FABRIC)

European Georges Pompidou Hospital

Status: Unknown

Conditions: Mantle Cell Lymphoma; Leukemia, Chronic Lymphatic

Study type: Observational

Funder types: Other

Identifiers

NCT04407845

00011928 FABRIC

Details and patient eligibility

About

Ibrutinib (a tyrosine kinase inhibitor targeting Bruton) is a standard of treatment in haematology. According to retrospective data, atrial fibrillation and systemic hypertension are common ibrutinib-related advserse events. The investigators aim at prospectively establishing the incidence of thesedrug related advsere events through clinical monitoring and attempt at identifying populations at risk.

Enrollment: 60 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All patients deem to start ibrutinib therapy

Exclusion criteria

• Past history of ibrutinib therapy